We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+9.29%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.5B
AUM Growth
-$325M
(-11%)
Cap. Flow
-$480M
Cap. Flow
% of AUM
-19.19%
Top 10 Holdings %
Top 10 Hldgs %
43.13%
Holding
114
New
31
Increased
17
Reduced
20
Closed
42
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$104M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$96.5M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$96.1M |
| 4 |
Thermo Fisher Scientific
TMO
|
+$86.3M |
| 5 |
Natera
NTRA
|
+$80.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$115M |
| 2 |
Incyte
INCY
|
+$95.4M |
| 3 |
Agios Pharmaceuticals
AGIO
|
+$79.2M |
| 4 |
AbbVie
ABBV
|
+$78.9M |
| 5 |
IQVIA
IQV
|
+$77.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.3% |
| 2 | Consumer Discretionary | 4.43% |
| 3 | Real Estate | 2.56% |
| 4 | Financials | 1.86% |
| 5 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Allogene Therapeutics
ALLO
$680M
| – | – |
-494,640
| Closed | -$17.5M |
|
77
Anika Therapeutics
ANIK
$270M
| – | – |
-13,540
| Closed | -$552K |
|
78
Aurinia Pharmaceuticals
AUPH
$2.07B
| – | – |
-950,000
| Closed | -$12.3M |
|
79
BioMarin Pharmaceuticals
BMRN
$11.9B
| – | – |
-227,450
| Closed | -$17.2M |
|
80
CALL
Celldex Therapeutics
CLDX
$3.26B
| – | – |
-255,000
| Closed | -$5.25M |
|
81
CONMED
CNMD
$1.49B
| – | – |
-276,940
| Closed | -$36.2M |
|
|
CNTB
82
Connect Biopharma Holdings
CNTB
$138M
| – | – |
-60,000
| Closed | -$1.11M |
|
83
Cooper Companies
COO
$14.3B
| – | – |
-452,668
| Closed | -$43.5M |
|
84
Curis
CRIS
$8.59M
| – | – |
-2,445
| Closed | -$11.1M |
|
85
eHealth
EHTH
$42.9M
| – | – |
-180,000
| Closed | -$13.1M |
|
86
Elevance Health
ELV
$84.9B
| – | – |
-91,760
| Closed | -$32.9M |
|
87
Guardant Health
GH
$21.1B
| – | – |
-219,300
| Closed | -$33.5M |
|
88
Haemonetics
HAE
$3.86B
| – | – |
-148,480
| Closed | -$16.5M |
|
89
ICU Medical
ICUI
$4.16B
| – | – |
-43,960
| Closed | -$9.03M |
|
|
90
Incyte
INCY
$24B
| – | – |
-1,144,287
| Closed | -$95.4M |
|
91
InnovAge Holding
INNV
$1.49B
| – | – |
-325,000
| Closed | -$8.38M |
|
|
92
IQVIA
IQV
$38.3B
| – | – |
-401,690
| Closed | -$77.6M |
|
93
PUT
iShares Russell 2000 ETF
IWM
$82.1B
| – | – |
-135,000
| Closed | -$29.8M |
|
94
MoonLake Immunotherapeutics
MLTX
$1.53B
| – | – |
-60,027
| Closed | -$613K |
|
95
Omeros
OMER
$952M
| – | – |
-50,000
| Closed | -$890K |
|
96
Qiagen
QGEN
$8.61B
| – | – |
-790,671
| Closed | -$40.8M |
|
97
PUT
Invesco QQQ Trust
QQQ
$479B
| – | – |
-90,000
| Closed | -$28.7M |
|
98
Ultragenyx Pharmaceutical
RARE
$2.54B
| – | – |
-207,610
| Closed | -$23.6M |
|
99
Arcus Biosciences
RCUS
$3.56B
| – | – |
-536,970
| Closed | -$15.1M |
|
100
Royalty Pharma
RPRX
$25.4B
| – | – |
-590,790
| Closed | -$25.8M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q2 2021 Portfolio in Review
As of Q2 2021, HealthCor Management held 114 positions worth $2.5B, down 11% from $2.83B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
HealthCor Management withdrew a net $480M in Q2 2021, closing 42 positions and reducing 20 holdings. Its most notable exit was Incyte, an estimated $95.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 84% a quarter earlier, followed by Consumer Discretionary and Real Estate.
Against the trend, HealthCor Management opened a new position in CVS Health worth $106M.
- HealthCor Management's largest Q2 2021 buy was CVS Health: 1,267,330 shares worth $106M.
- HealthCor Management added most to Biogen in Q2 2021, an estimated $78.4M increase.
- HealthCor Management's biggest Q2 2021 reduction was Vertex Pharmaceuticals, cutting an estimated $115M.
- HealthCor Management fully exited Incyte in Q2 2021, selling an estimated $95.4M.
- HealthCor Management's ten largest holdings make up 43% of its $2.5B portfolio in Q2 2021.
- HealthCor Management opened 31 new positions and closed 42 in Q2 2021.
- HealthCor Management's portfolio value fell 11% quarter-over-quarter to $2.5B.
Based on HealthCor Management's 13F filing for Q2 2021, filed 16 Aug 2021.